Researchers investigating viruses and vaccines have found Quansys Biosciences’ products and services useful. From measuring the baseline effects of viral infection in cells or mice, to verifying the efficacy of antiviral compounds or measuring alterations in TH1, TH2, and TH17 responses Quansys cytokine and chemokine kits are effective tools to aid your research. Quansys’ multiplexing technology is easily adapted to custom arrays that allow for the detection of antibodies to various antigens. Competitive inhibition of binding assays can also be performed.
Case Study: A 22-plex Chemiluminescent Microarray for Pneumococcal Antibodies
ARUP approached Quansys regarding a multiplex array to evaluate the efficacy of vaccine treatments with the Prevnar vaccine.The array was built with 22 different serotypes and compared to the Luminex assay. The results of the study were then published in the American Journal of Clinical Pathology in 2007. The Quansys Q-PlexTM technology was advantageous over the Luminex due to ease of use, lower inter and intra plate variation and reduction of costs, time and resources.
“A 22-plex Chemiluminescent Microarray for Pneumococcal Antibodies”
Authors: Jerry W. Pickering, Justin D. Hoopes, Matthew C. Groll, Heidi K. Romerol, Dave Wall, Howard Sant, Mark E. Astill and Harry R. Hill. American Journal of Clinical Pathology July 2007, 128:1
We developed a chemiluminescent multiplexed microarray that simultaneously determines IgG antibody concentrations to 22 pneumococcal polysaccharide (PnPs) serotypes (1, 2, 3, 4, 5, 6B, 7F, 8,9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 23F, and 33F). We compared the microarray with an enzyme-linked immunosorbent assay (ELISA) for 9 of the 22 serotypes (1, 4, 5, 6B, 9V, 14, 18C, 19F, and 23F). Correlation coefficients (r2) for the comparison of the microarray with ELISA ranged from 0.91 to 0.97 for the 9 serotypes. The microarray detected more than 4- fold increases in antibody concentrations in serum samples from before and 1 month after administration of pneumococcal vaccine for all 22 serotypes tested. The mean interassay and intra-assay coefficients of variation for 12 serum samples for the 22 serotypes were 7.6% and 6.0%, respectively. Inhibition-of-binding studies showed more than 90% inhibition by homologous serotypes and, with few exceptions, less than 25% inhibition by Heterologous serotypes. The microarray multiplexing technology is an attractive alternative to ELISA for antibody responses to 23-valent PnPs vaccines.